Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation

Abstract Background and Objective Fabry disease (FD) is a rare lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (aGal A). Since 2001, two different enzyme replacement therapies have been authorized, with agalsidase beta being used in most parts of the Western world....

Full description

Saved in:
Bibliographic Details
Main Authors: André B. P. van Kuilenburg (Author), Carla E. M. Hollak (Author), Ana Travella (Author), Melisa Jacobs (Author), Lucas D. Gentilini (Author), René Leen (Author), Karen M. M. Ghauharali-van der Vlugt (Author), Femke S. Beers Stet (Author), Susan M. I. Goorden (Author), Sanne van der Veen (Author), Marcelo Criscuolo (Author), Mariana Papouchado (Author)
Format: Book
Published: Adis, Springer Healthcare, 2023-04-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items